Some members of the media are ebullient with the news that Merck is "getting into venture capital." However, as In Vivo is reporting, Merck is undertaking two initiatives that are…
GSK announced that it has taken a ~25% stake in a new spin out. This is a terrific way to create new companies and advance more molecules into the clinic,…
Bruce Booth from Atlas Ventures has a fascinating story on his blog. We won't steal Bruce's thunder. Instead, we encourage you to read it there first. The gist of the story is…
There is a fascinating discussion taking place over at Derek Lowe's blog today on one-man drug companies: ...some of them are not quite down to one person, but you can…
Today's In Vivo Blog post summarizes comments that we have been hearing from our clients as well. Namely, that deals are increasingly shifting towards back-ended Royalties and earn-outs, at the…
We regret that we were unable to attend the panel discussions at BioTrinity last week. However, an excellent summary was posted on the PharmaPhorum web site. Of note: 1. Investment…
Fred Frank, a highly respected investment banker, greeted us on Tuesday morning with this missive: Venture capitalists, who make high-risk investments in start-ups, are tired of waiting years for biotech companies…
There has been a lot of commentary this week on Pfizer's announcement that their highly respected research center in Sandwich, UK, will be closed. The original press release suggested that…
There is a lot of good commentary and analysis of last week's JP Morgan Healthcare conference, most notably here, here, and here. Here are a few of our thoughts as…
In our meetings and informal discussions, there were three items we heard again and again: 1. Last year was a terrible fund raising year from a VC-backed company perspective. 2.…